OLANZA olanzapine 2.5 mg tablet blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

olanzapine, Quantity: 2.5 mg

Available from:

Arrotex Pharmaceuticals Pty Ltd

Pharmaceutical form:

Tablet, uncoated

Composition:

Excipient Ingredients: microcrystalline cellulose; lactose; hyprolose; magnesium stearate

Administration route:

Oral

Units in package:

28

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

OLANZA tablets are indicated for ? Treatment of schizophrenia and related psychoses. ? Short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar I disorder. ? Preventing recurrence of manic, mixed or depressive episodes in bipolar 1 disorder.

Product summary:

Visual Identification: Light yellow to yellow coloured, slightly mottled, round, biconvex tablets, debossed with 'O4' on one side and plain on the other side.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Authorization status:

Registered

Authorization date:

2020-07-01